VSIR and cancer: High expressions of VISTA on MDSCs in patients from a broad spectrum of cancers have been correlated to acquired resistance to anti-CTLA-4 and anti-PD-1/PD-L1 therapies, suggesting a compensatory inhibitory role of VISTA in certain malignancies [34].